Abstract
Aim: Diabetes is the most common cause of end stage renal disease (ESRD) and the target population in the dialysis clinics. An important question is why do so many diabetes patients develop ESRD and enter into dialysis? Our previous and other studies imply that over-enthusiastic use of angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocking (ARB) drugs contribute to the high incidence of ESRD in diabetes. Thus our aim was to investigate if ESRD in diabetes is preventable by glycemic control with intensive insulin therapy but with exclusion of ACEI/ARB drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
